Vectibix (panitumumab) / Dr. Reddy’s, Amgen, Takeda  >>  Phase 4
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vectibix (panitumumab) / Amgen
CCRe-IV, NCT02015923 / 2013-001688-22: Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases

Terminated
4
107
Europe
Colonic resection, Chemotherapy- scheme, FOLFOX-4, FOLFOX-6, FOLFIRI, FOLFOXIRI, CAPOX, CETUXIMAX / BEVACIZUMAB/PANITUMUMAB
Hospital Universitari de Bellvitge, Instituto de Salud Carlos III
Colonic Cancer, Unresectable Metastasis Originating in Colonic Cancer
06/19
02/20
2018-004231-72: Randomized study of the detection of mutations by BEAMing technology in advance of the radiological diagnosis of progression in patients with metastatic colorectal cancer and primary tumor in the left colon / rectum Estudio aleatorizado de la detección de mutaciones por tecnología BEAMing de forma anticipada al diagnóstico radiológico de la progresión en pacientes con cáncer colorrectal metastásico y tumor primario en el colon izquierdo/recto

Ongoing
4
80
Europe
Calcium Folinate, cetuximab, Hidrocloruro de irinotecán trihidrato, Oxaliplatino, panitumumab, L01XC06, , Solution for solution for injection, Solution for infusion, 5-Fluorouracilo, Calcium Folinate, Erbitux, Irinotecán, Oxaliplatino Teva, Vectibix
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS), Oncology Department
Median of the progression-free survival of patients with mCRC who maintains the treatment in conventional 1st line, QT + anti-EFGR, versus patients who withdraw anti-EGFR therapy after detection of mutations of the RAS gene / BRAF through the OncoBEAM ™ test. Comparar la mediana de supervivencia libre de progresión de pacientes con CCRm que mantienen el tratamiento en 1º línea convencional, QT + anti-EFGR, frente a la de los pacientes a los que se retira la terapia anti-EGFR tras la detección de mutaciones del gen RAS/BRAF mediante el test OncoBEAM™., Patients with colon-rectal cancer, primary tumor in left / rectum colon. Pacientes con Cáncer colo-rectal, tumor primario en colon izquierdo/recto., Diseases [C] - Cancer [C04]
 
 
2020-002533-14: Targeted therapy for advanced colorectal cancer patients. Terapia mirata per il trattamento dei pazienti con carcinoma metastatico del colon-retto.

Ongoing
4
106
Europe
Oxaliplatino, Irinotecan, Cetuximab, Panitumumab, Capecitabina, Bevacizumab, Fluorouracile, Calcio Folinato, ZALTRAP, [L01XA 03], [L01XX19], [L01XC06], [L01XC08], [L01BC06], [L01XC07], [L01BC02], [V03AF03], [L01XX44], Concentrate and solvent for concentrate for solution for infusion, Concentrate for solution for injection/infusion, Solution for injection/infusion, Film-coated tablet, Concentrate for solution for infusion, Powder for solution for injection
DIP. MEDICINA DEI SISTEMI UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATA, Unione Europea, Horizon 2020
unresectable metastatic colorectal cancer (mCRC) carcinoma del colon-retto metastatico (mCRC) non operabile, colorectal cancer Tumore del colon- retto, Diseases [C] - Cancer [C04]
 
 
NCT02301962: Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer

Unknown status
4
58
RoW
Panitumumab
Dr. Reddy's Laboratories Limited, Amgen
Cancer
06/21
01/22

Download Options